Brokerages Set Aspen Aerogels, Inc. (NYSE:ASPN) Target Price at $19.11

Aspen Aerogels, Inc. (NYSE:ASPN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $19.11.

A number of research analysts have recently commented on ASPN shares. TD Cowen raised Aspen Aerogels to a "strong-buy" rating in a report on Tuesday, March 11th. Craig Hallum lowered their price objective on Aspen Aerogels from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Friday, February 14th. Canaccord Genuity Group lowered their price objective on Aspen Aerogels from $20.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, February 14th. B. Riley lowered their target price on Aspen Aerogels from $35.00 to $22.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. Finally, Wall Street Zen raised Aspen Aerogels to a "sell" rating in a report on Wednesday, February 19th.

Aspen Aerogels Stock Down 3.3%

Aspen Aerogels stock traded down $0.22 during mid-day trading on Friday, hitting $6.46. The company's stock had a trading volume of 804,847 shares, compared to its average volume of 1,997,006. The firm's 50 day moving average is $5.77 and its 200 day moving average is $9.53. The company has a market cap of $530.15 million, a PE ratio of 40.54 and a beta of 2.72. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.93 and a quick ratio of 2.48. Aspen Aerogels has a 52-week low of $4.16 and a 52-week high of $33.15.

Aspen Aerogels (NYSE:ASPN - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The construction company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. Aspen Aerogels had a return on equity of 7.49% and a net margin of 2.95%. The company had revenue of $78.72 million during the quarter, compared to the consensus estimate of $82.75 million. During the same period last year, the business earned ($0.02) EPS. The business's quarterly revenue was down 16.7% on a year-over-year basis. On average, analysts anticipate that Aspen Aerogels will post 0.17 earnings per share for the current year.

Insider Transactions at Aspen Aerogels

In related news, CEO Donald R. Young bought 20,000 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was acquired at an average price of $5.35 per share, for a total transaction of $107,000.00. Following the transaction, the chief executive officer now directly owns 550,856 shares of the company's stock, valued at $2,947,079.60. This represents a 3.77% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 3.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Aspen Aerogels

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC raised its position in Aspen Aerogels by 333.8% in the 3rd quarter. Barclays PLC now owns 92,302 shares of the construction company's stock valued at $2,557,000 after purchasing an additional 71,024 shares during the last quarter. Ballentine Partners LLC raised its position in Aspen Aerogels by 19.2% in the 4th quarter. Ballentine Partners LLC now owns 15,914 shares of the construction company's stock valued at $189,000 after purchasing an additional 2,565 shares during the last quarter. Perigon Wealth Management LLC raised its position in Aspen Aerogels by 66.8% in the 4th quarter. Perigon Wealth Management LLC now owns 34,451 shares of the construction company's stock valued at $433,000 after purchasing an additional 13,796 shares during the last quarter. Journey Strategic Wealth LLC bought a new position in Aspen Aerogels in the 4th quarter valued at $178,000. Finally, Greenwood Capital Associates LLC raised its position in shares of Aspen Aerogels by 5.0% during the fourth quarter. Greenwood Capital Associates LLC now owns 36,938 shares of the construction company's stock worth $439,000 after acquiring an additional 1,749 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

About Aspen Aerogels

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.